Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 11

  • 1 291 clinical trials
  • 445 recruiting
  • 379 conditions
  • 29 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer332Asthma89Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV59Pulmonary arterial hypertension41COVID-1939Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Small cell lung cancer33Pneumonia32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza29Interstitial lung disease29Lung neoplasm malignant29Cystic fibrosis24Pulmonary hypertension24Conjunctivitis allergic23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 291 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 291 clinical trials

Respiratory tract infection

Recruiting

A study testing the safety and effectiveness of inhaled hypochlorous acid in patients with chronic airway infections

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · Healthy volunteers
  • Substances:Hypochlorous acid
  • Sponsor:Softox Solutions AS

Chronic obstructive pulmonary disease

Recruiting

Long-term Safety Study of Tozorakimab for Patients with Chronic Obstructive Pulmonary Disease and History of Exacerbations

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer

Recruiting

A Study of Telisotuzumab Adizutecan Compared to Standard Treatment in Adults with Advanced Non-Small Cell Lung Cancer After Previous Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Bladder cancer+4

Recruiting

Study of Heart and Blood Vessel Side Effects in Cancer Patients Receiving Immune Checkpoint Inhibitor Drug Combination Treatment

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Semmelweis University

Infantile apnoea

Recruiting

Testing Caffeine Citrate for Reducing Breathing Support Needs in Premature Newborns with Primary Apnea

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years
  • Substances:Caffeine Citrate
  • Sponsor:Masarykova Univerzita

Adenocarcinoma pancreas+1

Recruiting

A study testing ASP3082 in patients with advanced or spreading non-small cell lung cancer and pancreatic ductal adenocarcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Institut Gustave Roussy

Iron deficiency+1

Recruiting

A Study of Ferric Carboxymaltose to Improve Exercise Ability in Patients with Pulmonary Hypertension and Iron Deficiency

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Ziekenhuis Oost Limburg

Pulmonary hypertension

Recruiting

Testing Treprostinil Palmitil Inhalation Powder for Improving Exercise Ability in Patients with Pulmonary Hypertension Related to Interstitial Lung Disease

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil Palmitil
  • Sponsor:Insmed Inc.

Non-small cell lung cancer

Recruiting

Testing zongertinib compared to standard treatment in patients with early-stage non-small cell lung cancer with HER2 mutations after surgery

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Small cell lung cancer metastatic

Recruiting

Study of IDP-121 with chemotherapy for patients with relapsed small cell lung cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:IDP-121
  • Sponsor:Idp Discovery Pharma S.L.

Post-acute COVID-19 syndrome

Recruiting

A Study of Sonlicromanol for Reducing Fatigue in Patients with Long COVID

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Sonlicromanol hydrochloride
  • Sponsor:Amsterdam UMC Stichting

Pharyngitis

Recruiting

Testing benzydamine hydrochloride and dichlorobenzyl alcohol lozenges for relief of sore throat symptoms in patients with acute pharyngitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:2,4 dichlorobenzyl alcohol
  • Sponsor:MEDICE Arzneimittel Puetter GmbH & Co. KG

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin174 clinical trialsPembrolizumab149 clinical trialsCisplatin132 clinical trialsPemetrexed112 clinical trialsPaclitaxel83 clinical trialsDurvalumab71 clinical trialsAtezolizumab53 clinical trialsNivolumab50 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.